EPHB2 and neoplasm: Subsequent analyses uncovered tumor-cell-intrinsic mechanisms such as induction of apoptosis and downregulation of p-EGFR, p-AKT, p-ERK, and p-RAS40 levels, which underlie the synergistic anti-tumor activity of erlotinib+MLN0128.